Revance Therapeutics (RVNC) Tops Q3 EPS by 2c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/14/2026

1. AMAT
2. GLOB
3. SPY
4. RDDT
5. SNDK
6. HTFL
7. ADYEN:NA
8. ADYYF
9. WDAY
10. DVLT

Go back to Revance Therapeutics (RVNC) Tops Q3 EPS by 2c

Revance Therapeutics (RVNC) Reports Complete Enrollment in ASPEN-1 Phase 3 Pivotal Trial for Cervical Dystonia

November 4, 2019 5:26 PM EST

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced it has completed patient enrollment of the companys pivotal ASPEN-1 Phase 3 clinical trial for its investigational drug candidate DaxibotulinumtoxinA for Injection (DAXI) for the treatment of isolated cervical dystonia (CD), a movement disorder affecting the neck. In total, 301 adult patients were enrolled at 60 sites across the U.S., Canada and Europe.

The completion of patient enrollment in the ASPEN-1 trial marks an important milestone in our development efforts for DAXI and represents the first of many therapeutic indications we plan to pursue for our novel, long-acting... More

Revance Therapeutics (RVNC) Reports Publication of SAKURA 1 & SAKURA 2 Results in Plastic and Reconstructive Surgery

November 4, 2019 8:11 AM EST

Revance Therapeutics, Inc. (NASDAQ: RVNC) today announced the publication of results from the Phase 3 studies, SAKURA 1 and SAKURA 2, in Plastic and Reconstructive Surgery (PRS), the peer reviewed Journal of the American Society of Plastic Surgeons. These two Phase 3 studies evaluated Revances long-acting neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), for the treatment of moderate and severe glabellar lines.

This manuscript presents the findings from SAKURA 1 and 2 side-by-side, which demonstrate the consistency of efficacy and safety results evident between the two pivotal studies, as well as the reproducibility of these... More